European Commission Accepts Sanofi's Offer to Address Potential Anticompetitive Disparagement of Competing Flu Vaccine

European Commission made Sanofi's commitments legally binding to address concerns about its campaigns against Fluad, a competing flu vaccine. Sanofi agreed to correct misleading messages and avoid negative portrayals of Fluad until 2030. The company will also publish clarifying statements on its websites. SNY shares were up 0.59% in pre-market trading.

Sanofi avoided an EU fine by agreeing to stop disparaging rival flu vaccine Fluad (CSL Seqirus) in promotional materials. The EU investigated claims that Sanofi's Efluelda was safer, contradicting health recommendations. Sanofi committed to neutral messaging until 2030, with oversight. The case highlights EU scrutiny of promotional claims about competitors.

Sanofi (SNY) avoided an EU fine after proposing commitments to address allegations of disparaging CSL's (CSLLY) flu vaccine Fluad. The EU investigated claims Sanofi made about Fluad's efficacy compared to its own vaccine, Efluelda. Sanofi agreed to publish statements affirming both vaccines are equally recommended.

EU competition chief Teresa Ribera announced a record-fast antitrust settlement with Sanofi, securing benefits for millions receiving flu vaccines. The probe concluded in one year, with Sanofi committing to changes.

Sanofi avoided potential EU fines by agreeing to stop disparaging rival vaccine Fluad. The EU investigated claims Sanofi made about Fluad, which competes with its Efluelda vaccine. Sanofi will refrain from negative comparisons and publish clarifications on its websites.

Sanofi avoided a potential fine after the EU accepted its offer to stop disparaging CSL Seqirus's Fluad vaccine. The French pharma company proposed measures to address antitrust concerns, including halting negative promotional materials and publishing a clarification statement. The pledge lasts until 2030, according to the EU.